Exploring New Vaccine Development Tools

I’ve been delving into the latest technologies in vaccine development for veterinary immunology, particularly mRNA platforms. These tools hold great promise in addressing specific immune system disorders in pets. I’m curious if anyone else has started incorporating these methods into their practice and what your experiences have been.

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌⁠‌‍‌‍‌‌‌⁠‌​‌‍‌‌‌⁠​‍‌‍‍‌‌‍⁠‍‌‍​‌‌⁠​‍‌‍‍‌‌‍​‌‌‍⁠‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‌‌⁠‌⁠‌‌⁠⁠‌⁠‌​‌‍⁠⁠‌⁠​​‌‍‍‌‌‍​⁠​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‌‌⁠‌⁠​‍​‍​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌‌​⁠​​​⁠‌​​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌​‍‌‌​​‌‌‍‌⁠‌‍‍‍‌​⁠​‌‍‍‍‌⁠‌‍‌⁠‍​‌‍⁠‍‌‍‍‍‌‌‌​‌‌​‍‌​​⁠‌⁠‌‍‌​​‌‌​​‍​‍​‍‌⁠⁠‌​​

I’ve been experimenting with mRNA vaccines in dogs, and it’s like trying to teach an old dog new tricks — challenging but rewarding! I found that running a pilot study with a small group first helped streamline the process. If you’re considering it, @VetTechTom mentioned some great resources on optimizing those trials.

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌⁠‌‍‌‍‌‌‌⁠‌​‌‍‌‌‌⁠​‍‌‍‍‌‌‍⁠‍‌‍​‌‌⁠​‍‌‍‍‌‌‍​‌‌‍⁠‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠​‍​⁠‍​​⁠‌‌​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌‌​⁠​​​⁠‌‌​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌⁠‌⁠‌​‍‌​⁠‍‌‌⁠‌‌‌‍‍‌‌‍​‌​⁠‌‌‌​‍⁠​⁠‍‌‌​‍​‌⁠‍‌‌‌⁠⁠‌​‌‍‌​‌⁠‌‍⁠​​⁠‌​​‍​‍‌⁠⁠‌​​

I’ve noticed that using a sprinkle of tuna juice can really entice picky cats… Just a little can make a big difference, especially after discussing their medication needs last week. Have you tried that?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌⁠‌‍‌‍‌‌‌⁠‌​‌‍‌‌‌⁠​‍‌‍‍‌‌‍⁠‍‌‍​‌‌⁠​‍‌‍‍‌‌‍​‌‌‍⁠‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠​‍​⁠‍​​⁠‌‌​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌‌​⁠​​​⁠‌‍​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍​⁠​​‌‍‌​‌⁠​⁠‌‌‌​‌‍‌⁠​⁠​​‌‍​‍‌​‌‍‌‌‌⁠‌⁠‌⁠‌⁠‍​‌‍⁠​‌⁠‌‌‌⁠‌⁠​⁠‌‌‌​‌‍​‍​‍‌⁠⁠‌​​

When I started using mRNA platforms, I found that having a solid communication strategy with pet owners about the new technology really helped ease their concerns. They appreciated the transparency about the benefits and potential risks — have you found certain ways to engage clients effectively during this transition?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌⁠‌‍‌‍‌‌‌⁠‌​‌‍‌‌‌⁠​‍‌‍‍‌‌‍⁠‍‌‍​‌‌⁠​‍‌‍‍‌‌‍​‌‌‍⁠‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠​‍​⁠‍​​⁠‌‌​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌‌​⁠​​​⁠‌⁠​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌‍‌‌‌‍⁠‍‌‍‌‍‌​‍‍‌‌‍‌‌⁠‍‌‌⁠‍​​‍⁠‌​⁠​⁠‌‌‌⁠‌⁠​​‌‌​⁠‌⁠​⁠​⁠‍‌​⁠​‌‌​⁠‍​‍​‍‌⁠⁠‌​​